Posted inHematology-Oncology news Respiratory

Immunosuppression and Long-term Survival After Single Living-donor Lobar Lung Transplantation from the Same Donor as Prior Hematopoietic Stem Cell Transplantation: An All-Japan Case Series

This case series examines immunosuppressive management and long-term outcomes in nine Japanese patients undergoing single living-donor lobar lung transplantation from the same donor as prior HSCT, revealing viable reduced immunosuppression and favorable survival.
系统性硬化症中表型特异性的嵌合性染色体异常：对疾病亚型与临床结局的启示
Posted inHematology-Oncology news Rheumatology

Phenotype-Specific Mosaic Chromosomal Alterations in Systemic Sclerosis: Implications for Disease Subtypes and Clinical Outcomes

This article explores the differential associations of mosaic chromosomal alterations (mCAs), especially chromosomal loss and mosaic loss of the X chromosome, with systemic sclerosis and its subtypes, revealing phenotype-specific genetic contributions that may influence clinical manifestations and disease onset.
Impact of Clonal Hematopoiesis and Pre-treatment Neutropenia on CAR-T Cell Therapy Outcomes in Hematological Malignancies
Posted inHematology-Oncology news Oncology

Impact of Clonal Hematopoiesis and Pre-treatment Neutropenia on CAR-T Cell Therapy Outcomes in Hematological Malignancies

This study evaluates how clonal hematopoiesis of indeterminate potential (CHIP) and pre-treatment neutropenia affect clinical outcomes and toxicities in patients undergoing CAR-T therapy for hematologic cancers, revealing nuanced risks for specific toxicities without compromising survival outcomes.
Outcomes of Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults: Insights from the EBMT Chronic Malignancies Working Party
Posted inHematology-Oncology news

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults: Insights from the EBMT Chronic Malignancies Working Party

This retrospective study evaluates survival outcomes and risk factors associated with allogeneic hematopoietic cell transplantation in young adults (18-40 years) with myelodysplastic syndrome, revealing encouraging survival rates and highlighting critical prognostic variables for personalized transplant strategies.